Clinical Scorecard: FDA approves at-home dexmedetomidine for acute agitation
At a Glance
| Category | Detail |
|---|---|
| Condition | Acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder |
| Key Mechanisms | Dexmedetomidine is a highly selective alpha-2 adrenergic receptor agonist. |
| Target Population | Adults with acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder |
| Care Setting | At-home self-administration during agitation episodes; dexmedetomidine was previously approved for use under health care provider supervision. |
Key Highlights
- The FDA approved dexmedetomidine (Igalmi) sublingual film for at-home treatment of acute agitation in the specified adult populations.
- The approval was supported by SERENITY At-Home, a phase 3 randomized, double-blind, placebo-controlled safety and tolerability trial.
- The trial included 208 treated adults and 2,437 agitation episodes across both treatment groups.
- The trial was not powered to assess efficacy, although the study poster reported higher rates of complete agitation resolution with dexmedetomidine than placebo.
- Reported safety concerns include hypotension, orthostatic hypotension, and bradycardia.
Guideline-Based Recommendations
Diagnosis
Management
- The FDA approved dexmedetomidine sublingual film for at-home treatment of acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder in adults.
Monitoring & Follow-up
Risks
- The source identifies hypotension, orthostatic hypotension, and bradycardia as safety concerns, and lists cardiovascular conditions, history of syncope, hepatic impairment, and concomitant sedating medications as relevant precautions.
- In SERENITY At-Home, somnolence, including fatigue, was reported after the first treated episode in 22.5% of dexmedetomidine recipients and 17% of placebo recipients; dry mouth in 6.9% and 0.9%, respectively; and dizziness in 4.9% and 0.9%, respectively.
Patient & Prescribing Data
Adults with acute agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorder.
The at-home indication is for self-administration during agitation episodes. In the 12-week trial, tolerability was reported as consistent during repeat dosing; no dexmedetomidine recipients discontinued because of adverse events.
Clinical Best Practices
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
